MorphoSys Strengthens Patent Position on MOR202 Program
"In 2011, MOR202 became our third proprietary antibody program in clinical trials, following MOR103 in rheumatoid arthritis and multiple sclerosis and MOR208 in chronic lymphocytic leukemia," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Strengthening our intellectual property position on our proprietary products, particularly in our most important markets Europe, the USA and Asia, is of high priority for MorphoSys."
MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia. The HuCAL-derived, fully human antibody is currently being tested in a phase 1/2a trial in patients with relapsed/refractory myeloma.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous